Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin
about
JTT-705: is there still future for a CETP inhibitor after torcetrapib?Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk ReductionThe obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.The inhibition of cholesteryl ester transfer protein: a long and winding roadCholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL.Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.High-Density Lipoprotein - A Hero, a Mirage, or a Witness?Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.CETP inhibition in cardiovascular risk management: a critical appraisal.Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review.Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.Hepatic transforming growth factor-β 1 stimulated clone-22 D1 controls systemic cholesterol metabolism.Anacetrapib: hope for CETP inhibitors?Surrogate end points: how well do they represent patient-relevant end points?Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Emerging options in the treatment of dyslipidemias: a bright future?New horizons for cholesterol ester transfer protein inhibitors.On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.How can high-throughput screening deliver drugs to treat atherosclerosis?Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.Nanotechnology for synthetic high-density lipoproteinsIn vivo triglyceride synthesis in subcutaneous adipose tissue of humans correlates with plasma HDL parametersEarly termination of drug trials.Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.The failure of torcetrapib: is there a case for independent preclinical and clinical testing?The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism.Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?Crystal structure of CETP: new hopes for raising HDL to decrease risk of cardiovascular disease?
P2860
Q28294797-4D0DEB85-AF14-4825-8C94-DEF9BC80C9D4Q29999973-E3D94F48-2EE9-4A86-9A39-31737261FA7DQ30380628-C30E8A18-B8CB-4335-8EFD-157C495CFCE0Q33590777-664794EB-5173-410A-80DD-ED800CC20E51Q34441411-3B709D87-E688-45D4-813C-B736FCE980B8Q35034986-5111B3D4-1B23-4DB6-A293-A850EFDAD0BCQ35380101-8A55F53A-AF44-4812-AF77-B670B56109A5Q35958413-F2620BAE-DF54-48CB-A41B-2C3B889C589AQ36197563-2B9B1E56-4595-4EEA-A348-A9E4127EA64AQ36197709-F193B922-AEF1-42E7-8DFC-21321B95C288Q36344712-EC0BE244-F5F9-4327-B03E-E702B0728720Q36422727-A7CBC9CE-2892-458A-ADD3-5DBB9F22ADF7Q36705260-CE7921F7-3487-4AA5-8367-222F81DE680AQ36736504-FAB397D6-B251-4F70-A821-15A36A12919BQ36992708-A65B242B-13D1-4295-89DC-4F318118277FQ37163072-5320A3D3-4C19-4394-8FF4-99BFA75D3CA4Q37494202-86D5351C-0476-4DAF-8810-51104259EA5FQ37575509-A9207E45-ADFE-4DF3-8605-FE9CD42C3C20Q37636425-65CC3C9A-DE8A-4E64-ADE6-83CA0D6561B7Q37734553-FC1FFFEF-A9FA-491D-9CAD-D4F9BE98C066Q37755085-96A5F754-EECF-4E5C-B5C1-F22784BD8013Q37774393-F4927A1C-182C-483A-96FF-9D686264F7CDQ37827882-D8DB4B1C-B450-400A-9827-698FF367099AQ37842462-C950D2F7-2D77-4B5C-8907-6C56278E4A31Q37956122-E0E42668-01BE-4550-A743-5FDBECD967D2Q37987207-1CFFD595-3957-42CE-8166-3C0B517011B2Q38028514-A36738E2-A96F-4B82-AD03-4F4667738539Q38051303-C2F33679-2EE7-4B84-859B-71F2531E54D1Q38113494-60B7617A-B970-4C10-9379-67539E656044Q38203096-07E9E6BF-A971-41F5-945A-2192F795E481Q38741861-DB12C289-D4D0-476A-BAD1-E56506A5B6FDQ41516063-90878D35-B251-498D-A938-4296D7CBE15DQ42359779-A84B8660-2429-48DF-B3A8-C2A0609BBFC2Q42951671-B6F24E7B-545E-4318-AA71-1DD1F365167BQ46518415-F4DDB0B0-EC6A-4B49-93D5-C53D3AD9BE9BQ46673751-ADE86145-AEA3-4522-93FB-0E489EC12343Q46961293-45DCE4ED-B6F1-4F11-BD79-982DB5FAA35DQ47429427-72A62866-209A-4DE7-A679-7F2305FB83F3Q55043061-DE2102FD-499A-4959-A3C6-0816970F2889
P2860
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Efficacy and safety of torcetr ...... n a background of atorvastatin
@ast
Efficacy and safety of torcetr ...... n a background of atorvastatin
@en
Efficacy and safety of torcetr ...... n a background of atorvastatin
@nl
type
label
Efficacy and safety of torcetr ...... n a background of atorvastatin
@ast
Efficacy and safety of torcetr ...... n a background of atorvastatin
@en
Efficacy and safety of torcetr ...... n a background of atorvastatin
@nl
prefLabel
Efficacy and safety of torcetr ...... n a background of atorvastatin
@ast
Efficacy and safety of torcetr ...... n a background of atorvastatin
@en
Efficacy and safety of torcetr ...... n a background of atorvastatin
@nl
P2093
P1476
Efficacy and safety of torcetr ...... n a background of atorvastatin
@en
P2093
Charles L Shear
James H Revkin
James M McKenney
Michael H Davidson
P304
P356
10.1016/J.JACC.2006.06.066
P407
P577
2006-11-07T00:00:00Z